National Guideline Clearinghouse | Best evidence statement (BESt). Use of a clinical pathway in decreasing albuterol frequency in all patients up to 18 years of age admitted to the hospital with a diagnosis of asthma or reactive airway disease.

full-text:
National Guideline Clearinghouse Best evidence statement (BESt). Use of a clinical pathway in decreasing albuterol frequency in all patients up to 18 years of age admitted to the hospital with a diagnosis of asthma or reactive airway disease.

Guideline Title

Best evidence statement (BESt). Use of a clinical pathway in decreasing albuterol frequency in all patients up to 18 years of age admitted to the hospital with a diagnosis of asthma or reactive airway disease.

Bibliographic Source(s)

Cincinnati Children's Hospital Medical Center. Best evidence statement (BESt). Use of a clinical pathway in decreasing albuterol frequency in all patients up to 18 years of age admitted to the hospital with a diagnosis of asthma or reactive airway disease. Cincinnati (OH): Cincinnati Children's Hospital Medical Center; 2011 Aug 22. 5 p. [9 references]

Guideline Status

This is the current release of the guideline.